Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections
- PMID: 20643497
- PMCID: PMC2962678
- DOI: 10.1016/j.jhin.2010.05.023
Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections
Abstract
The prevalence of urinary tract infections caused by fluoroquinolone-resistant Gram-negative bacilli (FQ-resistant GNB-UTIs) has been increasing. Previous studies that explored risk factors for FQ resistance have focused only on UTIs caused by Escherichia coli and/or failed to distinguish colonisation from infection. We conducted a case-control study at two medical centres within the University of Pennsylvania Health System to identify risk factors for FQ resistance among healthcare-acquired GNB-UTIs. Subjects with positive urine cultures for GNB and who met Centers for Disease Control and Prevention criteria for healthcare-acquired UTI were eligible. Cases were subjects with FQ-resistant GNB-UTI and controls were subjects with FQ-susceptible GNB-UTI matched to cases by month of isolation and species of infecting organism. In total, 251 cases and 263 controls were included from 1 January 2003 to 31 March 2005. Independent risk factors (adjusted odds ratio; 95% confidence interval) for FQ resistance included male sex (2.03; 1.21-3.39; P=0.007), African-American race (1.80; 1.10-2.94; P=0.020), chronic respiratory disease (2.58; 1.18-5.62; P=0.017), residence in a long term care facility (4.41; 1.79-10.88; P=0.001), hospitalisation within the past two weeks (2.19; 1.31-3.64; P=0.003), hospitalisation under a medical service (2.72; 1.63-4.54; P<0.001), recent FQ exposure (15.73; 6.15-40.26; P<0.001), recent cotrimoxazole exposure (2.49; 1.07-5.79; P=0.033), and recent metronidazole exposure (2.89; 1.48-5.65; P=0.002).
Copyright © 2010 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Dr Lautenbach has received research support from Merck, Ortho-McNeil, Cubist, and AstraZeneca.
Similar articles
-
Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.J Antimicrob Chemother. 2015 May;70(5):1547-51. doi: 10.1093/jac/dku548. Epub 2015 Jan 27. J Antimicrob Chemother. 2015. PMID: 25630645 Free PMC article.
-
Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients.Epidemiol Infect. 2011 Jun;139(6):955-61. doi: 10.1017/S095026881000186X. Epub 2010 Aug 9. Epidemiol Infect. 2011. PMID: 20696087 Free PMC article.
-
Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary tract infections.BMC Infect Dis. 2017 Feb 28;17(1):176. doi: 10.1186/s12879-017-2270-7. BMC Infect Dis. 2017. PMID: 28241755 Free PMC article.
-
An update on the management of urinary tract infections in the era of antimicrobial resistance.Postgrad Med. 2017 Mar;129(2):242-258. doi: 10.1080/00325481.2017.1246055. Epub 2016 Oct 21. Postgrad Med. 2017. PMID: 27712137 Review.
-
Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.J Chemother. 2017 Dec;29(sup1):2-9. doi: 10.1080/1120009X.2017.1380395. J Chemother. 2017. PMID: 29271736 Review.
Cited by
-
Stimulating Transcription in Antibiotic-Tolerant Escherichia coli Sensitizes It to Fluoroquinolone and Nonfluoroquinolone Topoisomerase Inhibitors.Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0163922. doi: 10.1128/aac.01639-22. Epub 2023 Mar 23. Antimicrob Agents Chemother. 2023. PMID: 36951560 Free PMC article.
-
Prevalence and Factors Associated With Multidrug-Resistant Gram-Negative Organisms in Patients With Spinal Cord Injury.Infect Control Hosp Epidemiol. 2017 Dec;38(12):1464-1471. doi: 10.1017/ice.2017.238. Epub 2017 Nov 21. Infect Control Hosp Epidemiol. 2017. PMID: 29157323 Free PMC article.
-
Susceptibility pattern of uropathogens to ciprofloxacin at the Ghana police hospital.Pan Afr Med J. 2015 Oct 1;22:87. doi: 10.11604/pamj.2015.22.87.6037. eCollection 2015. Pan Afr Med J. 2015. PMID: 26848334 Free PMC article.
-
Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.J Antimicrob Chemother. 2015 May;70(5):1547-51. doi: 10.1093/jac/dku548. Epub 2015 Jan 27. J Antimicrob Chemother. 2015. PMID: 25630645 Free PMC article.
-
Prevalence and risk factor analysis of resistant Escherichia coli urinary tract infections in the emergency department.Pharm Pract (Granada). 2013 Apr;11(2):96-101. doi: 10.4321/s1886-36552013000200006. Epub 2013 Jun 30. Pharm Pract (Granada). 2013. PMID: 24155856 Free PMC article.
References
-
- Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259–268. - PubMed
-
- Smith JT. Mutational resistance to 4-quinolone antibacterial agents. Eur J Clin Microbiol. 1984;3:347–350. - PubMed
-
- Cullmann W, Stieglitz M, Baars B, Opferkuch W. Comparative evaluation of recently developed quinolone compounds – with a note on the frequency of resistant mutants. Chemotherapy. 1985;31:19–28. - PubMed
-
- Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med. 2002;162:2469–2477. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
